Advertisement
Screener

Monte Rosa Therapeutics, Inc. (GLUE) Cash Flow Breakdown

Monte Rosa Therapeutics, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Monte Rosa Therapeutics, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $22.80M went out.
  • Fiscal year ended 2025-12-31: from investing, $101.83M went out.
  • Fiscal year ended 2025-12-31: from financing, $30.35M came in.
  • Fiscal year ended 2025-12-31: change in cash, $94.28M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDividendsNew shares soldNot split outChange in cash
2025-12-31-$22.80M-$101.83M$0.00$5.72M$24.63M*-$94.28M
2024-12-31$42.00M-$44.45M$0.00$1.06M$97.83M*$96.44M
2023-12-31-$43.80M$88.80M$2.03M$25.46M*$72.49M
2022-12-31-$92.47M-$219.22M$0.00$20.05M-$291.22M
2021-12-31-$59.36M-$9.65M$0.00$0.00$377.56M*$308.55M
2020-12-31-$23.05M-$3.39M$0.00$60.06M*$33.62M

Each quarter (3 month)

Quarter endRunning the businessFrom investingDividendsNew shares soldNot split outChange in cash
2026-06-30-$44.11M*-$28.86M*$0.00*$2.60M*$611.00K*
2026-03-31-$37.37M-$261.00M$0.00$4.52M$323.81M*$29.97M
2025-12-31-$43.01M*-$65.07M*$0.00*$5.36M*$24.26M*
2025-09-30$100.43M*$38.14M*$0.00*$0.00*
2025-06-30-$34.72M*$25.32M*$0.00*$0.00*
2025-03-31-$45.49M-$100.23M$0.00$14.00K-$145.71M
2024-12-31$128.92M*-$30.90M*$0.00*$379.00K*
2024-09-30-$20.99M*$37.75M*$0.00*$0.00*
2024-06-30-$27.77M*-$61.16M*$0.00*$421.00K*$97.60M*
2024-03-31-$38.16M$9.85M$0.00$246.00K-$28.07M
2023-12-31$29.63M*$14.30M*$0.00*$14.00K*$25.16M*
2023-09-30-$24.71M*$35.63M*$0.00*$1.10M*
2023-06-30-$25.32M*$18.55M*$0.00*$897.00K*
2023-03-31-$23.41M$20.33M$0.00$18.00K-$3.06M
2022-12-31-$23.96M*-$53.94M*$0.00*$6.55M*$13.89M*
2022-09-30-$20.60M*$29.49M*$0.00*$79.00K*
2022-06-30-$20.50M*-$14.25M*$0.00*$96.00K*
2022-03-31-$27.40M-$180.52M$0.00$153.00K-$207.77M
2021-12-31-$14.17M*-$3.05M*$0.00*$0.00*
2021-09-30-$17.79M*-$1.69M*$0.00*$0.00*$29.46M*
2021-06-30-$13.58M*-$2.70M*$128.00K*$205.34M*
2021-03-31-$13.81M-$2.22M$0.00$142.77M*$126.74M
2020-12-31-$8.57M*-$1.19M*$0.00*
2020-09-30-$6.89M*-$930.00K*$0.00*$47.75M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Vor Biopharma Inc. (VOR)United States$1.091B1.60
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10